Evidence map›Paper›PMID 40178731›Full record

ArticlePulmonary therapy2025

The Role of Surgery in Pleural Mesothelioma: A Journey through the Evidence, MARS 2 and Beyond.

Avinash Aujayeb, Philippe Astoul, Francesco Londero, Andrea Zuin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Avinash AujayebRespiratory Department, Northumbria Health Care NHS Foundation Trust, Care of Gail Hewitt, Newcastle, NE23 6NZ, UK. avinash.aujayeb@nhct.nhs.uk.ORCID http://orcid.org/0000-0002-0859-5550
Philippe AstoulDepartment of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, North Hospital, Aix-Marseille University, Marseille, France.
Francesco LonderoThoracic Surgery Unit, Cardiothoracic Department, University Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Andrea ZuinThoracic Surgery Unit, Cardiothoracic Department, University Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pleural mesothelioma (PM) is a rare incurable disease, predominantly linked to asbestos exposure. Not only is diagnosis difficult, but treatment choices are often limited to systemic anti-cancer treatment with chemotherapy or immunotherapy. Surgery has been employed for decades, but its application has been fiercely debated despite some randomized controlled trials such as the recent Mesothelioma and Radical Surgery 2 (MARS 2) study. We provide a commentary on this controversial topic.

Indexed as

ChemotherapyImmunotherapyMARS 2Pleural mesotheliomaPleurectomyPneumonectomySurgery

Identifiers

PMID40178731
PMCPMC12102037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.